PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32913968-5	2017	Results: We observed that abiraterone-resistant tumors harbored alterations in AR and MYC, whereas enzalutamide-resistant tumors gained alterations in cell-cycle pathway genes, such as mutation in cyclin-dependent kinase N2A (CDKN2A) or amplification of CDK6.	enzalutamide	99-111	cyclin dependent kinase inhibitor 2A	Homo sapiens	197-224	
32913968-5	2017	Results: We observed that abiraterone-resistant tumors harbored alterations in AR and MYC, whereas enzalutamide-resistant tumors gained alterations in cell-cycle pathway genes, such as mutation in cyclin-dependent kinase N2A (CDKN2A) or amplification of CDK6.	enzalutamide	99-111	cyclin dependent kinase inhibitor 2A	Homo sapiens	226-232